CASI Pharmaceuticals
CASI
CASI was delisted on the 25th of February, 2026.
53 hedge funds and large institutions have $63.2M invested in CASI Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 20 increasing their positions, 14 reducing their positions, and 6 closing their positions.
74% more capital invested
Capital invested by funds: $36.4M → $63.2M (+$26.8M)
43% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 14
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
4% more funds holding
Funds holding: 51 → 53 (+2)
0.98% more ownership
Funds ownership: 1.14% → 2.12% (+0.98%)
Top Buyers
| 1 |
WSC
Wellington Shields & Co
New York
|
+$4.14M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$268K |
| 3 |
State Street
Boston,
Massachusetts
|
+$247K |
| 4 |
Morgan Stanley
New York
|
+$175K |
| 5 |
BlackRock
New York
|
+$163K |
Top Sellers
CASI Hedge Fund Activity: Q4 2019 in Review
53 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in CASI Pharmaceuticals (CASI) for Q4 2019, worth a combined $63.2M — up 74% from $36.4M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new CASI positions and 6 closed out — a net gain of 2 holders — while 20 added to existing stakes and 14 trimmed.
The largest buyer was Wellington Shields & Co, opening a new position worth an estimated $4.14M. The largest seller was Northern Trust, cutting an estimated $132K.
- 53 institutional investors held CASI Pharmaceuticals (CASI) as of Q4 2019, up from 51 in Q3 2019.
- Funds reported $63.2M of CASI Pharmaceuticals stock for Q4 2019, up 74% quarter-over-quarter.
- 8 funds opened new CASI Pharmaceuticals positions in Q4 2019 and 6 closed out, a net change of +2 holders.
- The largest CASI Pharmaceuticals buyer in Q4 2019 was Wellington Shields & Co, an estimated $4.14M added.
- The largest CASI Pharmaceuticals seller in Q4 2019 was Northern Trust, an estimated $132K sold.
Based on aggregated 13F filings for Q4 2019.